E215 - The PsychopharmaStahlogy Show: Untreatable Dimensions of Psychopathology: Anhedonia with Dr. Vladimir Maletic

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer’s Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

How does dysfunction in cognition affect overall treatment outcomes for psychiatric disorders? What are the challenges in treating cognitive deficits in psychiatric conditions? What treatments are in development for cognitive dysfunction? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Richard Keefe and Dr. Stephen Stahl about the clinical difficulties of treating cognitive dysfunction.  Let’s listen to Part 2 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode! ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are some common challenges faced by caregivers of individuals with dementia? What is comprehensive dementia care and how does it improve quality of life of individuals with dementia and their caregivers? What is the GUIDE Model and why is it needed?  Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a Professor at the Nell Hodgson Woodruff School of Nursing at Emory University. Dr. Clevenger is a nationally recognized educational leader in advanced practice nursing and in geriatrics and gerontology. She is a Past President of the Gerontological Advanced Practice Nurses Association, Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America, and contributor to the AANP Certification Program. She is the director of the nurse-led patient centered medical home for people living with dementia, the Integrated Memory Care Clinic (IMCC). IMCC represents an innovative clinical model that provides memory and primary care in a single integrated model for people living with dementia and their care partners.  Resources Alzheimer’s Association KAER toolkit ROON   ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What is the role of mindfulness techniques in the treatment of anxiety disorders and how is it evolving? How does mindfulness-based stress reduction compare to pharmacological treatment for anxiety disorders? What are the hypotheses that have been made about why mindfulness-based treatments work for anxiety? Elizabeth Hoge, MD is a Professor and Director of the Anxiety Disorders Research Program in the Department of Psychiatry at Georgetown University School of Medicine. Dr. Hoge completed her psychiatry residency training and research fellowship at the Massachusetts General Hospital in Boston. During her research fellowship, she earned a Masters in Medical Science from the Harvard Medical School-Massachusetts Institute of Technology program in Health Sciences and Technology with a focus on clinical trials. Her research focuses on treatments for anxiety disorders, including medication, psychotherapy and mindfulness, and the examination of biomarkers of anxiety, stress, and trauma. She has over 50 publications in the medical research literature and is on the Scientific Council of the Anxiety and Depression Association of America. ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are the cultural factors that should be considered when providing mental health care to migrant and refugee populations? What challenges and opportunities exist in providing mental health care to these communities? How can mental health professionals collaborate with other disciplines to create a holistic approach to address the mental health needs of migrant and refugee populations?  Lisa Fortuna, MD, MPH is the Chief of Psychiatry and Neurosciences at the Riverside School of Medicine. She was the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital/UCSF and Associate Professor of Clinical Psychiatry. She has been an investigator on several National Institutes of Health and foundation-funded studies of Latino and immigrant mental health, integrated care, access to care including a principle investigator of a NIMH funded R01 aimed at optimizing family navigation for addressing child behavioral health in primary care and a Patient Centered Outcome Research Institute (PCORI) funded multi-site large pragmatic trial on the treatment of childhood anxiety comparing face to face vs. digitally delivered CBT in English and Spanish called Kids FACE FEARS. Her areas of expertise are child and adolescent psychiatry, treatment and research on PTSD across the lifespan, immigrant mental health and disparities/ access to care including digital interventions research. 

How does anhedonia impact the overall treatment plan for patients with major depressive disorder and other psychiatric conditions? What are some of the most challenging aspects of treating anhedonia in patients? Are there any new treatments in development that may be helpful for treating anhedonia? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Vladmir Maletic and Dr. Stephen Stahl about the clinical difficulties of treating anhedonia  Let’s listen to Part 1 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode!